Section 1. Basic Principles of Pharmacology

Slides:



Advertisements
Similar presentations
Module II The Basics of the Brain, the Body and Drug Actions
Advertisements

Introduction to Pharmacology
LAKSHMAN KARALLIEDDE OCTOBER 2011
Pharmacology for Anesthesia I Introduction. What is a Drug?
DISPOSITION OF DRUGS The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill,
DRUG-RECEPTOR INTERACTIONS
Principles of Pharmacology. SOURCES AND NAMES OF DRUGS Sources of Drugs Many drugs are isolated from plants or chemically derived from plant substances.
Pharmacokinetics -- part 1 --
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Definitions Pharmacokinetics –The process by which a drug is administered, absorbed, distributed, bound, inactivated, metabolized and eliminated by the.
Principles of Pharmacology Pharmacokinetics & Pharmacodynamics
Asmah Nasser, M.D. Pharmacokinetics.
Pharmacokinetics Chapter 4.
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Principles of Pharmacology: Pharmacodynamics
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 2 Drug Action and Handling.
Pharmacodynamics Pharmacodynamics Department of pharmacology Yang Fangju( 杨芳矩)
Principles of Pharmacology: Pharmacodynamics
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
Pharmacokinetics Introduction
Lecture 2.  Clearance Ability to eliminate the drug  Volume of distribution (Vd) The measure of the apparent space in the body available to contain.
PHARMACOKINETICS.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Pharmacology Department
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
 all drugs not in gaseous state need to use fluid routes of excretion ◦ fluid routes include -sweat, tears, saliva, mucous, urine, bile, human milk ◦
PHARMACOKINETICS Part 3.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
PHARMACOKINETICS Definition: quantitative study of drug absorption, distribution, metabolism, and excretion (ADME), and their mathematical relationship.
PHARMACODYNAMICS M.T. Piascik PHA 824 November 11, 2008.
DEFINITIONS T1/2 & Tmax Cmax AUC 1st order kinetics
Dr. Laila M. Matalqah Ph.D. Pharmacology Pharmacodynamics 2 General Pharmacology M212.
Clinical Pharmacokinetics. Time course Duration Onset Absorptive phase Elimination phase.
METABOLISME DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA dr. Yunita Sari Pane.
CHAPTER 4 L. VanValkenburg, RVT, BAS Pharmacokinetics.
DRUG RECEPTORS AND PHARMACODYNAMICS
Section 1, Lecture 8 Receptor Classification according to: -which drugs they interact with (  -adrenergic –binds norepinphine with high affinity.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Physiology for Engineers
Basic Principles: PK By: Alaina Darby.
Pharmacology Phone Number: (203)
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
MBBS-BDS LECTURE NOTES
Understanding the Basics of Pharmacology
به نام خدا فارماکوکینتیک نیمسال دوم دکتر ساسان زائری
Pharmacokinetics Chapter 4
INTRODUCTION to Pharmacology
Pharmacologic Principles – Chapter 2
Pharmacokinetics and Factors of Individual Variation
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Hawler Medical University
Pharmacology UG-Course
1 Concentration-time curve
Basic Biopharmaceutics
Biopharmaceutics Chapter-6
Chapter 2 Pharmacodynamics (PD)
Therapeutic Drug Monitoring chapter 1 part 1
Introduction to Pharmacology
By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology
Introduction to Pharmacology
CHAPTER 4 l. VanValkenburg, RVT, BAS
Section 1, Lecture 2 PHARMACOKINETICS [DRUG]
Efficacy, Potency and Safety of Drugs
Introduction to Pharmacology
Pharmacokinetics Asst Prof Dr Inam S. Arif
Drug Metabolism.
Drug- Receptor Interaction
Objectives To discuss what happens after drug administration
Presentation transcript:

Section 1. Basic Principles of Pharmacology Chapter 1 Introduction 【Definition of Pharmacology】 Relationship between drug and body 【Contents of Pharmacology】 1. Pharmacodynamics drug  body 2. Pharmacokinemics 【Drugs and toxins】 【Diseases from drugs】 【Relative subjects】 Clinical Pharmacology Drug therapeutics Toxicology

Chapter 2 Pharmacodymamics 【Characteristics of drug effects】 Modulate the original function of body: Excitation or Inhibition 【Selectivity of drug effects】 For any drug: comparable; depending on properties of drug, dose, and routes 【Consequences of drug actions】 1. Therapeutic effect Purposes inc. etiological and symptomatic 2. Untoward reaction 1) Side reaction 2) Toxic reaction inc. acute, chronic, and unusual toxicities (carcinogenesis, teratogenesis, mutagenesis, reproductive toxicity, etc) 3) After effect (residual effect) 4) Allergic reaction and idiosyncratic reaction 5) Dependence of drugs 【Dose-effect relationship】 1. Graded dose-response relationship

1) The chart of graded dose-effect relationship: 2) Relative parameters: EC50 and KD Potency Efficiency (Efficacy, Intrinsic activity) 2. Quantal dose-response relationship “All or No” response 1) The chart of quantal dose-effect relationship: Median effective dose (ED50) Median lethal dose (LD50) Therapeutic index (TI) 【Mechanism of drug action】 1. Receptor Properties of receptor: (1) stereo-specificity; (2) high effectiveness; (3) saturability; (4) reversibility; (5) versatility; (6) modification.

2. Ligand Binding with special receptor; Standard: high affinity to receptor 1) Full agonist 2) Partial agonist 3) Antagonist 4) Partial inverse agonist 5) Full inverse agonist 3. Evaluation parameters of affinity 1) PD2 2) pA2 4. Drug-Receptor Theory 1) Occupation theory Clark A.J. (1933) V1 L + R = LR ----- E V2 v1=k1.[L][R], v2=k2.[LR], k2/k1=KD= [L].[R]/[LR], [LR] = [L].[R]/KD

Effect/Emax = [LR]/[RT] = [LR]/[R]+[[LR] = ([L]. [R]/KD)/([R]+[L] Effect/Emax = [LR]/[RT] = [LR]/[R]+[[LR] = ([L].[R]/KD)/([R]+[L].[R]/KD) = ([L].[R]/KD)/{([R].KD+[L].[R])/KD} Effect/Emax = [L]/(KD+[L]) When effect = ½.Emax, ie [LR]=1/2.[ RT] , [L]=KD 2) Two-state theory (allosteric theory) 5. The interaction of drugs on the receptor levels 1) Competitive antagonism (agonist – competitive antagonist) 2) Non-competitive antagonism (agonist – non-competitive antagonist) 3) Competitive dualism (agonist – partial agonist)

Chapter 3 Pharmacokinetics 1. Drug transport across the biomembranes 1) Drug transport styles (1) Passive membrane transport Sort: filtration and simple diffusion; the later is very important. Feature: No energy is needed; No carrriers are needed; No saturability; The factors that influence on the drug simple diffusion : A. aspect of drug: lipophilicity, ionization level , pKa, molecular size and shape; B. aspect of transport circumustances: areas, pH, blood flow) HA (weak acid) B (weak base) HA  H+ + A BH+  B + H+ Ka = [HA] / [H+][A] Ka = [BH+] / [B][H+] log Ka =  log([H+][A] / [HA]) log Ka = log([B][H+] / [BH+]) = log[H+]  log([A] / [HA]) = log[H+]  log([B] / [BH+]) pKa = pH  log([A] / [HA]) pKa = pH + log([BH+] / [B]) pH  pKa = log([A] / [HA]) pKa  pH = log([BH+] / [B])

(2) Carrier-mediated membrane transport Sort: active transport (feature: just opposite to passive transport) facilitate transport (feature: No energy is needed) 2. Drug absorption 1) Definition 2) Factors of influence (1) The factors that influence drug transport (2) The factors from drug preparations 3) Evaluation parameters (1) First pass effect (2) Bioavailability F = (amount of absorption/administration dose)  100% F = [AUC(extravascular)/AUC(intravenous)]  100% … absolute bioavailability F = [AUC(sample)/AUC(standard)]  100% … relative bioavailability

3. Drug distribution 1) Definition 2) Factors of influence (1) Factors that influence drug transport (2) Affinities and binding of drug to plasma proteins and special tissues or organs (3) The barriers of organs ( such as blood-brain barrier, blood-eye barrier, and placenta barrier) 3) Parameters of evaluation Apparent volume of distribution (Vd) Vd = total amount of drug in body/concentration of drug in plasma 4. Biotransformation 2) Phases of biotransformation including phase I and phase II 3) Main responsible enzymes — Cytochrome P-450 monoxygenase system, also called as hepatic microsomal drug enzymes 4) Properties of the enzymes: (1) low specificity, (2) large individual difference, (3) saturability, (4) variable activity of enzumes Inducer: phenobarbital, phenytoin, rifampin, … Inhibitor: cimetidine, isoniazid, chloromycetin, …

5. Drug excretion 1) Definition 2) Routes of excretion (1) Kindeys including glomerular filtration, tubular active transport, and tubular passive re-absorption. (2) Milk (3) Bile enterohepatic recycle 6. Pharmacokinetics of drug elimination 1) Concentration-time curve of drug (1) Cmax (2) Tpeak (3) AUC (4) TC 2) Essential conceptions (1) Compartment (2) Compartment models (3) Serum elimination half-life (t1/2) (4) Steady state concentration (Css) consisting of Css peak and Css valley

3) The elimination of first-order kinetics (1) Feature: The drug concentrations in plasma follow a exponential pattern of decline (constant ratio elimination). The elimination half-life is a constant. t1/2 = 0.693/k (2) Clinical uses: Estimate the time that is needed for drug to be eliminated thoroughly from body. Estimate the time that is needed for drug to reach the Css after a certain amount of drug is given at regular time intervals. If a certain amount of drug is given orally at regular time intervals, it is very convenient to arrive at Css by doubling first dose. If drug is given iv gtt, 5 fold of t1/2 time is needed to arrive at Css without Css peak and valley. decreasing dose, shortening time interval, but keeping the total dose (that is given at same time intervals) not changed will diminish the difference between Css peak and Css valley. 4) Zero-order kinetics Feature: constant amount elimination; elimination half-life is not constant